A citation-based method for searching scientific literature


List of co-cited articles
149 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
361
68

The Parkinson Pandemic-A Call to Action.
E Ray Dorsey, Bastiaan R Bloem. JAMA Neurol 2018
316
25

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh, Jong-Sung Park, Seung-Hwan Kwon, Yong Joo Park, Senthilkumar S Karuppagounder, Hyejin Park,[...]. Nat Med 2018
444
25

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
291
25

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
478
25

Diabetes, a Contemporary Risk for Parkinson's Disease: Epidemiological and Cellular Evidences.
Domenico Sergi, Justine Renaud, Nicola Simola, Maria-Grazia Martinoli. Front Aging Neurosci 2019
36
25

A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
Chenhui Ji, Guo-Fang Xue, Cao Lijun, Peng Feng, Dongfang Li, Lin Li, Guanglai Li, Christian Hölscher. Brain Res 2016
65
25


Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
Alexander Zimprich, Saskia Biskup, Petra Leitner, Peter Lichtner, Matthew Farrer, Sarah Lincoln, Jennifer Kachergus, Mary Hulihan, Ryan J Uitti, Donald B Calne,[...]. Neuron 2004
18

Alpha-synuclein in Lewy bodies.
M G Spillantini, M L Schmidt, V M Lee, J Q Trojanowski, R Jakes, M Goedert. Nature 1997
18

The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Julia L Y Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie, Alastair J Noyce. J Parkinsons Dis 2020
46
18

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H Ridha,[...]. Trials 2019
83
18


Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
235
18

Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis.
Emanuele Cereda, Michela Barichella, Carlo Pedrolli, Catherine Klersy, Erica Cassani, Riccardo Caccialanza, Gianni Pezzoli. Diabetes Care 2011
139
18


Diabetes mellitus and Parkinson disease.
Gennaro Pagano, Sotirios Polychronis, Heather Wilson, Beniamino Giordano, Nicola Ferrara, Flavia Niccolini, Marios Politis. Neurology 2018
99
18

Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
Dilan Athauda, Kate Maclagan, Natalia Budnik, Luca Zampedri, Steve Hibbert, Iciar Aviles-Olmos, Kashfia Chowdhury, Simon S Skene, Patricia Limousin, Thomas Foltynie. Eur J Neurosci 2019
32
18

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
58
18

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce. Mov Disord 2021
30
18

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
172
18


GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
412
18




The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
Lingyu Zhang, Liping Zhang, Yanwei Li, Lin Li, Josefine Ulrikke Melchiorsen, Mette Rosenkilde, Christian Hölscher. J Parkinsons Dis 2020
37
18

Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Miroslaw Brys, Laura Fanning, Serena Hung, Aaron Ellenbogen, Natalia Penner, Minhua Yang, Mackenzie Welch, Erica Koenig, Eric David, Tara Fox,[...]. Mov Disord 2019
84
12

Pathogenesis of Parkinson's disease.
Etienne C Hirsch, Peter Jenner, Serge Przedborski. Mov Disord 2013
174
12



Emerging therapies in Parkinson disease - repurposed drugs and new approaches.
Ahmad Elkouzi, Vinata Vedam-Mai, Robert S Eisinger, Michael S Okun. Nat Rev Neurol 2019
110
12

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.
Michael A Schwarzschild, Alberto Ascherio, M Flint Beal, Merit E Cudkowicz, Gary C Curhan, Joshua M Hare, D Craig Hooper, Karl D Kieburtz, Eric A Macklin, David Oakes,[...]. JAMA Neurol 2014
162
12

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Stephen Mullin, Laura Smith, Katherine Lee, Gayle D'Souza, Philip Woodgate, Josh Elflein, Jenny Hällqvist, Marco Toffoli, Adam Streeter, Joanne Hosking,[...]. JAMA Neurol 2020
130
12

Parkinson disease.
Werner Poewe, Klaus Seppi, Caroline M Tanner, Glenda M Halliday, Patrik Brundin, Jens Volkmann, Anette-Eleonore Schrag, Anthony E Lang. Nat Rev Dis Primers 2017
12

Personalized medicine in Parkinson's disease: Time to be precise.
Nataliya Titova, K Ray Chaudhuri. Mov Disord 2017
85
12

Glucocerebrosidase Mutations in Parkinson Disease.
Grace O'Regan, Ruth-Mary deSouza, Roberta Balestrino, Anthony H Schapira. J Parkinsons Dis 2017
72
12


LRRK2 in Parkinson disease: challenges of clinical trials.
Eduardo Tolosa, Miquel Vila, Christine Klein, Olivier Rascol. Nat Rev Neurol 2020
166
12

alpha-Synuclein locus triplication causes Parkinson's disease.
A B Singleton, M Farrer, J Johnson, A Singleton, S Hague, J Kachergus, M Hulihan, T Peuralinna, A Dutra, R Nussbaum,[...]. Science 2003
12

Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain.
Wen Li, Elisabet Englund, Håkan Widner, Bengt Mattsson, Danielle van Westen, Jimmy Lätt, Stig Rehncrona, Patrik Brundin, Anders Björklund, Olle Lindvall,[...]. Proc Natl Acad Sci U S A 2016
168
12

Clinical progression in Parkinson disease and the neurobiology of axons.
Hsiao-Chun Cheng, Christina M Ulane, Robert E Burke. Ann Neurol 2010
528
12

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.
Mike A Nalls, Cornelis Blauwendraat, Costanza L Vallerga, Karl Heilbron, Sara Bandres-Ciga, Diana Chang, Manuela Tan, Demis A Kia, Alastair J Noyce, Angli Xue,[...]. Lancet Neurol 2019
625
12

A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.
Alessio Di Fonzo, Christan F Rohé, Joaquim Ferreira, Hsin F Chien, Laura Vacca, Fabrizio Stocchi, Leonor Guedes, Edito Fabrizio, Mario Manfredi, Nicola Vanacore,[...]. Lancet 2005
408
12

Progress in unraveling the genetic etiology of Parkinson disease in a genomic era.
Aline Verstraeten, Jessie Theuns, Christine Van Broeckhoven. Trends Genet 2015
146
12

Biomarkers of Parkinson's disease: present and future.
Diane B Miller, James P O'Callaghan. Metabolism 2015
182
12

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
12

GLP-1 receptor agonists for Parkinson's disease.
Caroline A Mulvaney, Gonçalo S Duarte, Joel Handley, David Jw Evans, Suresh Menon, Richard Wyse, Hedley Ca Emsley. Cochrane Database Syst Rev 2020
19
12

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
962
12

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
601
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.